Pfizer

What Pfizer does

Pfizer is a public, large-cap biopharmaceutical company (NYSE: PFE) founded in 1849, headquartered in New York, with approximately 75,000 employees, 36 manufacturing sites, and commercial reach across roughly 200 countries and territories. It discovers, develops, manufactures, and commercializes prescription medicines and vaccines across four therapeutic franchises: oncology (Ibrance, Padcev, Tukysa, Talzenna, Elrexfio), inflammation and immunology (Litfulo, Hympavzi, Xeljanz), vaccines (Comirnaty, Abrysvo, pipeline Lyme and PCV25 candidates), and internal medicine (Nurtec for migraine, plus an emerging obesity pipeline centered on berobenatide). Its underlying technology platforms include mRNA, antibody-drug conjugates (acquired via Seagen), and multispecific/bispecific antibody engineering.

The company monetizes primarily through one-time drug sales to healthcare providers (field sales via PfizerPro), governments and payers (notably for COVID-19 vaccine procurement), and increasingly patients directly via PfizerForAll and Pfizer RxPathways assistance programs; licensing and royalty income is a secondary stream. Pfizer supplements organic R&D with an aggressive M&A program that has consumed over $77B in disclosed deal value since 2021 (Trillium $2.26B, Arena $6.7B, GBT $5.4B, Biohaven $11.6B, Seagen $43B, Metsera $10B), with the Seagen transaction financed in part through a $31B bond offering. As of May 5, 2026, the pipeline contains 96 projects (35 Phase 1, 25 Phase 2, 31 Phase 3, 5 Registration), and FY2025 revenue was $62.6B with Q1 2026 revenue of $14.45B (+5.4% YoY) and five consecutive quarterly earnings beats.

Name

Pfizer

Legal name

Pfizer Inc.

Website

https://pfizer.com

Company type

Public

Founded year

1849

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Pfizer is a global biopharmaceutical company (NYSE: PFE) that discovers, develops, and commercializes prescription medicines and vaccines across oncology, inflammation and immunology, vaccines, and internal medicine for healthcare providers, governments, and patients in approximately 200 countries.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Oncology & Hematology Pharmaceuticals (HLAIAAAC), Immunology & Inflammation Pharmaceuticals (HLAIAAAD), Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Travel & Tropical Disease Vaccines (HLAIAEAE)

Keywords

• Prescription pharmaceuticals
• Biopharmaceutical medicines
• Oncology therapeutics
• Vaccines and biologics
• Antibody drug conjugates

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Marketing or Sales, Supply Chain, Operations, Personnel, Infrastructure, Others

Revenue model

1. Pharmaceutical Drug Sales: Sales of prescription pharmaceutical medicines across multiple therapeutic areas including oncology, internal medicine, inflammation & immunology, and vaccines
2. Vaccine Sales: Sales of human vaccines including COVID-19 vaccines (Comirnaty), RSV vaccines (Abrysvo), and pipeline vaccines
3. Debt Financing: Pfizer raised $31 billion through bond offerings to fund acquisitions including Seagen
4. Licensing and Royalalties: Revenue from licensing intellectual property and royalty arrangements from partner products

Pricing tiers

Go-to-market motion2 records

Distribution channels5 records

Marketing channels11 records

Core offering

Pfizer discovers, develops, manufactures, and commercializes branded prescription medicines and vaccines across four therapeutic areas: Oncology, Inflammation & Immunology, Internal Medicine, and Vaccines. Its marketed portfolio includes IBRANCE, PADCEV, TUKYSA, TALZENNA, ELREXFIO, LITFULO, NURTEC, HYMPAVZI, ABRYSVO, Comirnaty, Paxlovid, Eliquis and Vyndaqel/Vyndamax, sold globally in approximately 200 countries through direct field sales, pharmacy distribution, and government procurement. A 96-program R&D pipeline (as of May 5, 2026) supports continued launches in oncology ADCs, obesity/GLP-1, vaccines and rare disease.

Product overview

Pfizer is a biopharmaceutical company with a diversified portfolio of marketed medicines and vaccines plus a robust pipeline spanning multiple therapeutic areas. The core portfolio includes oncology treatments (IBRANCE, PADCEV, TUKYSA, TALZENNA, ELREXFIO), anti-infectives (ABRYSVO RSV vaccine, NURTEC for migraines), inflammation/immunology drugs (LITFULO, HYMPAVZI), and internal medicine products. The pipeline includes numerous candidates across Phase 1-3, with significant investment in obesity/GLP-1 therapies (berobenatide acquired from Metsera), antibody-drug conjugates from the Seagen acquisition (sigvotatug vedotin, fetrastobart vedotin), and a Lyme disease vaccine with Valneva. Key strategic acquisitions include Seagen ($43B for oncology ADCs), Arena Pharmaceuticals ($6.7B for etrasimod), and Trillium Therapeutics ($2.26B for CD47 biologics).

Differentiator

Problem solved

Functional benefit

Brands

• Pfizer CentreOne: Contract manufacturing and pharmaceutical services division
• Pfizer RxPathways
• PfizerForAll
• PfizerPro
• Accord for a Healthier World
• Breakthrough Fellowship Program
• Pfizer Ventures

Products and services

• IBRANCE (palbociclib) CDK4/6 inhibitor for HR+/HER2+ locally advanced or metastatic breast cancer, used as maintenance therapy in combination with trastuzumab and endocrine therapy after induction treatment.
• PADCEV (enfortumab vedotin) Antibody-drug conjugate targeting Nectin-4 for metastatic urothelial (bladder) cancer, co-developed with Astellas; Q1 2026 sales of $591M, up 39% year-over-year.
• TUKYSA (tucatinib) HER2 kinase inhibitor for HER2+ metastatic breast cancer; studied in HER2CLIMB-05 for 1L HER2+ metastatic breast cancer maintenance.
• TALZENNA (talazoparib) PARP inhibitor studied in combination with XTANDI for 1L HRRm metastatic castration-sensitive prostate cancer (TALAPRO-3 Phase 3).
• ELREXFIO (elranatamab) BCMA-directed bispecific antibody for multiple myeloma; being studied in MagnetisMM-5 for double-class exposed relapsed/refractory multiple myeloma.
• HYMPAVZI (marstacimab) Anti-tissue factor pathway inhibitor approved for hemophilia A and B with inhibitors; studied for moderate hemophilia A/B without inhibitors.
• LITFULO (ritlecitinib) JAK inhibitor approved for chronic spontaneous urticaria, Crohn's disease, hidradenitis suppurativa, ulcerative colitis; studied for vitiligo (TRANQUILLO) and moderate alopecia areata.
• NURTEC ODT (rimegepant) CGRP receptor antagonist for acute migraine treatment; 41% growth in Q1 2026 and being studied for chronic migraine and redosing in acute treatment.
• ABRYSVO Respiratory syncytial virus (RSV) vaccine approved for use including pediatric and older-adult populations.
• Comirnaty (COVID-19 mRNA vaccine) mRNA COVID-19 vaccine co-developed with BioNTech, distributed globally including via government procurement and national immunization programs.
• Paxlovid (COVID-19 oral antiviral) Oral antiviral treatment for COVID-19, used in pandemic response and stockpiled by governments and health systems.
• Eliquis (apixaban) Anticoagulant with $13B+ annual US revenue; subject to upcoming patent cliff.
• Vyndamax / Vyndaqel (tafamidis) ATTR amyloidosis treatment with patent protection extended through June 2031; $6.4 billion in 2024 sales.
• Xeljanz (tofacitinib) JAK inhibitor for autoimmune conditions; peaked at $2.45B in 2021, declined to ~$1.09B by 2025 following FDA safety warnings.
• Berobenatide (PF'3944 / MET-097i) Biologic GLP-1 receptor agonist for chronic weight management; Phase 2b data supports monthly subcutaneous dosing option; acquired from Metsera.

Quantifiable outcome

• Q1 2026 revenue of $14.45 billion, up 5.4% year-over-year
• +3 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• Innovent BiologicscoreStrategic or Co-development Partner · 29 June 2026Pfizer and Innovent Biologics partnership on GLP-1 drugs including ecnoglutide, which cleared preliminary review for potential inclusion in China's basic medical insurance drug catalogue for weight management and type II diabetes treatment.
• MetseracoreStrategic or Co-development Partner · 1 November 2025Pfizer acquired Metsera for approximately $10 billion following a bidding war with Novo Nordisk, gaining access to obesity drug pipeline including PF'3944 (berobenatide) and MET-097i for monthly dosing GLP-1 treatments. The acquisition positions Pfizer to compete in the $100-150B obesity market against Eli Lilly and Novo Nordisk.
• SeagencoreStrategic or Co-development Partner · 16 May 2023Pfizer acquired Seagen for approximately $43 billion to become a leader in oncology ADCs. The acquisition included Padcev (enfortumab vedotin) and a broad ADC pipeline. Pfizer funded $31 billion through an eight-tranche bond deal to finance the acquisition.
• Global Blood Therapeutics (GBT)coreStrategic or Co-development Partner · 8 August 2022Pfizer acquired Global Blood Therapeutics for $5.4 billion to strengthen presence in rare hematology, particularly sickle cell disease treatments. The acquisition included approved drug Oxbryta and pipeline candidate GBT601 with combined potential peak sales of over $3 billion.
• ResApp HealthminorStrategic or Co-development Partner · 12 April 2022Pfizer Australia proposed to acquire digital health company ResApp for AU$100 million as part of strategic expansion efforts in digital health technology.
• Arena PharmaceuticalscoreStrategic or Co-development Partner · 11 March 2022Pfizer completed $6.7 billion acquisition of Arena Pharmaceuticals to expand immuno-inflammatory treatment portfolio, gaining late-stage treatment candidate etrasimod targeting inflammatory bowel diseases.
• Trillium TherapeuticscoreStrategic or Co-development Partner · 23 August 2021Pfizer acquired Trillium Therapeutics for approximately $2.26 billion in cash (118% premium) to strengthen oncology pipeline with biologics targeting the CD47 pathway for hematological malignancies, including Phase 1b/2 trials.
• ValnevacoreStrategic or Co-development PartnerPfizer and Valneva co-development of Lyme disease vaccine candidate (PF-07307405/VLA15), with Pfizer conducting pediatric clinical trials as the companies seek regulatory approval for the first Lyme disease vaccine since the late 1990s.
• Astellas PharmacoreStrategic or Co-development PartnerPfizer and Astellas co-development agreement for PADCEV (enfortumab vedotin) in bladder cancer. European Commission approved KEYTRUDA plus Padcev combination for muscle-invasive bladder cancer based on KEYNOTE-905 trial conducted with Pfizer and Astellas.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Novartis: Novartis is a directly comparable peer in oncology (including CDK4/6 inhibitors like Kisqali that compete with Ibrance), cardiovascular, and immunology, with a similar recent focus on focused innovation-driven pharma after shedding non-core units.
• AbbVie: AbbVie is a directly comparable peer in immunology (Humira/Skyrizi/Rinvoq vs Pfizer's Litfulo/Xeljanz), oncology, and neuroscience, with similar reliance on a few mega-blockbusters and aggressive M&A to refresh the portfolio.
• Roche Holding: Roche is a directly comparable peer in oncology biologics, vaccines, and diagnostics, with significant overlap in ADCs, bispecifics, and personalized healthcare that mirror Pfizer's Seagen-acquired ADC and multispecific antibody capabilities.
• Sanofi: Sanofi is a directly comparable peer in vaccines, immunology (Dupixent), rare disease, and increasingly in metabolic/obesity via its partnership pipeline, with overlapping distribution, manufacturing, and primary-care commercial models.
• GSK: GSK is a directly comparable peer in vaccines (Shingrix, Arexvy vs Comirnaty/Abrysvo), specialty pharmaceuticals, and HIV, and previously co-owned Pfizer's consumer health business, making it a particularly tight comparator in vaccine commercial models.
• AstraZeneca: AstraZeneca is a directly comparable peer in oncology ADCs (Enhertu being a direct rival to Pfizer's Padcev franchise), oncology biologics, rare disease (post-Alexion), and respiratory/biologics, with overlapping pipeline focus and similar revenue scale.
• Bristol-Myers Squibb: Bristol-Myers Squibb is a directly comparable peer in oncology (Opdivo, Yervoy vs Pfizer's Ibrance, Padcev, Tukysa), cardiovascular (Eliquis co-promote partner of Pfizer's in some markets), and immunology, with a similar revenue scale and patent-cliff challenges.
• Merck & Co. Merck competes head-on with Pfizer in oncology (Keytruda vs Pfizer's Seagen ADCs and Ibrance), vaccines, and hospital specialty care, with a similar model of high-revenue biologics facing near-term patent cliffs and aggressive business-development to refill the pipeline.
• Eli Lilly: Eli Lilly is a directly comparable large-cap biopharma peer with overlapping therapeutic areas including oncology, immunology, diabetes, and - most prominently - the obesity GLP-1 franchise (Zepbound/Mounjaro, retatrutide) that is now Pfizer's primary competitive frontier after the Metsera acquisition.

Broad incumbents

• Johnson & Johnson (Innovative Medicine): Johnson & Johnson's Innovative Medicine segment (Janssen) competes with Pfizer across oncology, immunology, pulmonary hypertension, and infectious diseases, while J&J's broader MedTech and consumer businesses position it as a larger, more diversified incumbent.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/pfizer
• YouTubeyoutube.com/pfizer
• Facebookfacebook.com/pfizer
• LinkedInlinkedin.com/company/pfizer
• Instagraminstagram.com/pfizerinc

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries7 records

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A43 records

Investments59 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pfizer